Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions

被引:41
作者
Abdelrahim, Mohamed E. [1 ,2 ]
机构
[1] Univ Beni Suef, Fac Pharm, Dept Clin Pharm, Bani Suwayf, Egypt
[2] Univ Tours, Fac Med, Tours, France
关键词
Terbutaline sulphate; Turbuhaler; Dose emission; Urine samples; Inhalation twice; DRY POWDER INHALERS; OBSTRUCTIVE PULMONARY-DISEASE; FLOW-RATE; DELIVERY CHARACTERISTICS; DRUG-DELIVERY; INHALATION; SALBUTAMOL; BUDESONIDE; FORMOTEROL; EFFICACY;
D O I
10.1016/j.rmed.2009.11.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Turbuhaler has a very high resistance hence patient inhalation flow when using it would be low. The total emitted dose (TED) of 500 mu g terbutaline sulphate from a Bricanyl Turbuhaler was determined using a range of inhalation flows (10-60 L min(-1)) with inhalation volume of 2 and 4 L using a DPI sampling apparatus after one and two inhalations. The relative lung and systemic bioavailability of terbutaline from Bricanyl Turbuhaler when used by healthy subjects and COPD patients were determined after one and two inhalations at slow and fast inhalation flows using a novel urinary terbutaline pharmacokinetic method. The TED resulted from the one and two inhalations increased significantly (p < 0.05) with the increase of the inhalation flow at both 2 and 4 L inhalation volumes. The relative lung and systemic bioavailability after one inhalation at fast inhalation flow were significantly higher (p < 0.01) than at slow inhalation flow in both healthy subjects and patients. Also the healthy subjects results were significantly higher (p < 0.05) than the COPD patients after one inhalation. However after two inhalations there was no significant difference between slow and fast inhalation flow or healthy subjects and COPD patients. Hence it is essential to inhale twice and as deep and hard as possible from each dose of Turbuhaler for patients with low inspiratory flow and limited inhalation volume as they may not receive much benefit from one inhalation. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:682 / 689
页数:8
相关论文
共 31 条
[1]  
ABDELRAHIM ME, 2007, J PHARM PHARM, V59, pA39
[2]  
ABDELRAHIM ME, 2007, J AEROSOL MED, V20, P16
[3]  
[Anonymous], AM J RESP CRIT CARE
[4]  
*BOARD TRUST, 2005, US PHARM, P2359
[5]   The inhalation device influences lung deposition and bronchodilating effect of terbutaline [J].
Borgstrom, L ;
Derom, E ;
Stahl, E ;
WahlinBoll, E ;
Pauwels, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (05) :1636-1640
[6]   LUNG DEPOSITION OF BUDESONIDE INHALED VIA TURBUHALER(R) - A COMPARISON WITH TERBUTALINE SULFATE IN NORMAL SUBJECTS [J].
BORGSTROM, L ;
BONDESSON, E ;
MOREN, F ;
TROFAST, E ;
NEWMAN, SP .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (01) :69-73
[7]   Inhalation profiles in asthmatics and COPD patients: Reproducibility and effect of instruction [J].
Broeders, MEAC ;
Molema, J ;
Hop, WCJ ;
Folgering, HTM .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2003, 16 (02) :131-141
[8]   PEAK INSPIRATORY FLOW-THROUGH TURBUHALER(R) IN ACUTE ASTHMA [J].
BROWN, PH ;
NING, ACWS ;
GREENING, AP ;
MCLEAN, A ;
CROMPTON, GK .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (11) :1940-1941
[9]   Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [J].
Calverley, PM ;
Boonsawat, W ;
Cseke, Z ;
Zhong, N ;
Peterson, S ;
Olsson, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) :912-919
[10]   Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD [J].
Cazzola, M ;
Noschese, P ;
De Michele, F ;
D'Amato, G ;
Matera, MG .
RESPIRATORY MEDICINE, 2006, 100 (02) :212-217